Skip to main content
Knowledge4Policy
Knowledge4Policy (K4P)

Supporting policy with scientific evidence

We mobilise people and resources to create, curate, make sense of and use knowledge to inform policymaking across Europe.

Targeted alpha therapy: a promising option for treatment-resistant cancers

  • Story | 04 Nov 2025
Science Insights

Takeaways

  • Targeted alpha therapy provides a powerful option for treatment-resistant cancers, especially prostate cancer, a major cause of cancer death in men. 
  • The JRC has been a pioneer in developing Targeted Alpha Therapy and in producing and supplying the radioactive materials (Actinium 225) needed for cancer treatment.
  • An eightfold increase in the number of patients eligible for radioligand therapies is expected over the next 10 years.
  • Therefore, there is a critical demand for Actinium-225. It is vital to invest in steady production and transportation to treat all future patients.

Read the 2-page document 

 

The figure shows the expected increase of radioligand therapies in the next 10 years. Source: Holzwarth (2025) Anticipating the Wave: How Many Patients? How Soon? EANM Congress 2025 Presentation

Alpha
More information and links
Originally Published | Last Updated

04 Dec 2025 | 26 Aug 2026

Publisher | MetadataScience Insights
Digital Europa Thesaurus (DET)cancer
Related reading
PAGE | 20 Jul 2026
Melomanes SES Edition
The Scenario Exploration System to reflect on the ethical issues of therapies for malignant melanoma
More
Privacy statements, terms and conditions.
You will be directed to the EU Login website where you can login/register as a user. Once connected, your credentials (First name, last name, username, email) will be registered in Knowledge4policy as part of your profile, which will allow you to get involved in all Knowledge4policy communities (help is available).
You are leaving EUROPA

You are about to navigate to an external website. Please note that we are not responsible for its content.